Skip to content
    Clinical Trials

    Neoadjuvant Carboplatin Improves pCR and EFS in Early-Stage TNBC

    Felsheim et alJCO oncology advances

    Neoadjuvant Carboplatin Improves pCR and EFS in Early-Stage TNBC
    A pooled analysis of 1,084 patients from three randomized clinical trials—BrighTNess (NCT02032277), CALGB 40603 (Alliance; NCT00861705), and GeparSixto (NCT01426880)—evaluated the therapeutic impact of adding carboplatin to anthracycline- and taxane-based neoadjuvant chemotherapy (NACT) in early-stage triple-negative breast cancer (TNBC). Investigators evaluated pathologic complete response (pCR) rates, event-free survival (EFS), and overall survival (OS), alongside associations with germline BRCA1 and BRCA2 (gBRCA) mutation status, eight gene expression signatures, and molecular subtypes (PAM50, MDACC/BCM).
    In the overall pooled dataset, adding carboplatin to NACT was associated with a higher pCR rate (odds ratio = 1.89, 95% confidence interval [CI] = 1.41–2.55, p < 0.001) and improved EFS (hazard ratio = 0.71, 95% CI = 0.54–0.93, p = 0.01), but did not show an association with OS. In the subgroup of patients with gBRCA mutations (n = 137), carboplatin addition conveyed a significant EFS benefit but showed no significant association with pCR rate or OS.
    Biomarker assessments identified six immune gene expression signatures that were significantly associated with higher pCR rates and four signatures significantly associated with improved EFS and OS. Conversely, the PAM50 luminal and MDACC/BCM luminal androgen receptor (LAR) molecular subtypes were significantly associated with lower pCR rates. The study authors concluded that these findings support the incorporation of carboplatin into NACT as standard of care for stage II–III TNBC and emphasize the clinical significance of the tumor immune microenvironment.

    Key Takeaways

    • In the pooled cohort of 1,084 patients, adding carboplatin to neoadjuvant chemotherapy was associated with a higher pathologic complete response rate (OR = 1.89, 95% CI = 1.41–2.55, p < 0.001) and improved event-free survival (HR = 0.71, 95% CI = 0.54–0.93, p = 0.01), but not overall survival.
    • Among patients with germline BRCA1/2 mutations (n = 137), the addition of carboplatin conveyed a significant event-free survival benefit, although no significant association was observed with pathologic complete response rate or overall survival.
    • Molecular profiling showed six immune gene expression signatures were significantly associated with higher pCR and four with improved EFS and OS, whereas PAM50 luminal and MDACC/BCM LAR molecular subtypes were significantly associated with lower pCR rates.
    Read the original sourceJCO oncology advances